• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Omega-3s and Metabolic Risks in Schizophrenia
RESEARCH UPDATE

Omega-3s and Metabolic Risks in Schizophrenia

September 28, 2021
Batya Swift Yasgur, MA, LSW, and Chris Aiken, MD.
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Batya Swift Yasgur, MA, LSW, and Chris Aiken, MD. The authors have disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

REVIEW OF: Pawełczyk T et al, Schizophr Res 2021;230:61–68

TYPE OF STUDY: Randomized, double-blind, placebo-controlled trial

Patients with schizophrenia are at greater risk for metabolic syndrome, whether from lifestyle, antipsychotic side effects, or the illness itself. Omega-3 fatty acids have metabolic benefits in the general population, and levels of these “healthy fats” tend to be low in people with schizophrenia. Earlier research found that omega-3 supplementation improved negative symptoms in schizophrenia, and this study examined their metabolic effects in schizophrenia.

This was a randomized, double-blind, placebo-controlled trial of 71 adults with stable schizophrenia on antipsychotic medication. They were treated with either omega-3 fatty acids or a fish-flavored placebo for six months. Both the placebo and the active intervention contained 0.2% alpha-tocopherol (vitamin E) to prevent oxidation of fatty acids. The omega-3 intervention consisted of a 3:1 ratio of eicosapentaenoic (EPA) and docosahexaenoic (DHA) acids with a total daily dosage of 2,200 mg/day. Body composition and metabolic parameters associated with metabolic syndrome were assessed at baseline, then at eight and 26 weeks after study initiation. Both groups began the trial with similar metabolic parameters.

After eight weeks, the placebo group had a nonsignificant increase in metabolic syndrome (p = 0.083), and this increase was even greater at 26 weeks (p = 0.007). By contrast, the rate of metabolic syndrome decreased in the treatment group, although the effect was just marginally significant (p = 0.0408). Notably, the omega-3 group had significant reductions in fasting blood glucose (p = 0.045), total cholesterol (p = 0.037), and blood glucose levels (p = 0.034), but improvements in other metabolic parameters were not significant. Patients on olanzapine experienced the greatest metabolic benefits with omega-3s.

The investigators also found an association between triglyceride level and the psychopathology subscale of the Positive and Negative Syndrome Scale, suggesting that lower triglycerides are associated with improved symptoms of psychopathology (p = 0.0008).

Omega-3s were well tolerated in this study. They have a mild anticoagulant effect, but patients on anticoagulants may still be able to take omega-3s with approval from their prescribing physician. Omega-3 supplementation may deplete vitamin E, which notably was supplemented in this study.

The 3:1 EPA:DHA ratio used in this study can be difficult to find but is worth the search, as this is also the ratio that worked in studies of depression. We found three products with a similar ratio that were tested by independent labs: Viva Naturals (on Amazon), Member’s Mark (at Sam’s Club), and Kirkland Signature (at Costco) at a cost of 15–25 cents/day.

TCPR’s Take
This study is small and preliminary, but omega-3s have established benefits for metabolic health in various conditions and are worth considering in schizophrenia.

General Psychiatry Research Update
KEYWORDS comorbidity complementary-treatments complimentary-medicine diabetes metabolic-syndrome negative-symptoms psychosomatics research-update schizophrenia
    Batya Swift Yasgur, MA, LSW,

    More from this author
    Aiken
    Chris Aiken, MD.

    How to Use Lamotrigine

    More from this author
    www.thecarlatreport.com
    Issue Date: September 28, 2021
    SUBSCRIBE NOW
    Table Of Contents
    The Schizophrenia-OCD Overlap
    Light Therapy: Good for What Ails You?
    How to Diagnose ADHD in Bipolar Disorder
    Brexpiprazole Ineffective in Mania
    Omega-3s and Metabolic Risks in Schizophrenia
    CME Post-Test - Mood Disorder, TCPR, October 2021
    DOWNLOAD NOW
    Featured Book
    • MFB7e_Print_App_Access.png

      Medication Fact Book for Psychiatric Practice, Seventh Edition (2024) - Regular Bound Book

      The updated 2024 reference guide covering the most commonly prescribed medications in psychiatry.
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2603816031.jpg
      General Psychiatry

      A Scam for Every Woman, Child, and Man: Part 2

      1 in 3 Americans were victims of online scams in the past year. Even when you know your patient is being scammed, it is hard to pull them out. We speak with Cathy Wilson about...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.